Wednesday
SESSION 31: NEW DEVELOPMENTS AND ADVANCES IN MEDICAL AND ANTI-ATHEROGENIC TREATMENTS FOR PATIENTS WITH ARTERIAL DISEASE
Location: Grand Ballroom West, 3rd Floor
Moderators:Mehdi H. Shishehbor, DO, MPH, PhD / Geno J. Merli, MD, MACP, FHM, FSVM  
SESSION 31 SCHEDULE
6:40 AM - 6:45 AM How Long Should Patients With DVT Be Kept On Anticoagulants: A Review Of The Data
  Presenter(s):Geoffrey Barnes, MD, MSc  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
6:46 AM - 6:51 AM What Are The New AHA Hypertension Guidelines And Why All PAD Patients Should Be Treated According To These Guidelines
  Presenter(s):Jeffrey W. Olin, DO  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
6:52 AM - 6:57 AM Benefits Of Cilostazol Before And After Peripheral Endovascular Procedures: What Regimen And Dosage Should Be Given Routinely
  Presenter(s):Gary M. Ansel, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
6:58 AM - 7:03 AM What Is Anacetrapib: Do CETP Inhibitors To Reduce LDL Cholesterol (LDL-C) More Than Statins Have A Role In PAD Patients: What About Ezetemibe (Zetia): How Low An LDL-C Should We Try To Get
  Presenter(s):Kavita Sharma, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:04 AM - 7:09 AM PCSK-9 Inhibitors: Highlights For The Vascular Specialist In 2018
  Presenter(s):Pradeep Natarajan, MD, MMSc  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:10 AM - 7:15 AM DEBATE: Statins Are Dangerous Drugs: Lowering LDL-C Does No Good And Is Harmful In Most Patients
  Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:16 AM - 7:21 AM DEBATE: Not So: Lowering LDL-C Levels With Statins And PCSK-9 Inhibitors In At Risk Patients With PAD Prevents Cardiovascular Events And Deaths; It Is Safe And Prolongs Life
  Presenter(s):Ron Waksman, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:22 AM - 7:27 AM How Important Is It To Give High Intensity Statins To PAD Patients: How Low Should We Push Their LDL-C, To <50 mg/dL; What About Adding Other Drugs: What About Statins In Older (>80) PAD Patients
  Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC  / Caron B. Rockman, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:28 AM - 7:33 AM DEBATE: What Did The COMPASS RCT Show: After This Trial, Rivaroxaban Plus Aspirin Should Be Given To All PAD Patients To Lower Their Risk Of Stroke, MI And Death: What Doses
  Presenter(s):Jay Giri, MD, MPH  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:34 AM - 7:39 AM DEBATE: Not So Fast: We Still Need To Know More Before Adding Rivaroxaban For PAD Patients
  Presenter(s):Brian H. Annex, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:40 AM - 7:46 AM Panel Discussion
END OF SESSION 31
previous next